Core Insights - The Joint Corp. reported a 6% increase in revenue for Q3 2025, reaching $13.4 million compared to $12.7 million in Q3 2024 [5][7][12] - The company authorized an additional $12 million for share repurchases, reflecting confidence in its growth and profitability strategies [5][11] Financial Performance - Revenue for the first nine months of 2025 was $39.7 million, up 6% from $37.4 million in the same period of 2024 [12] - Consolidated net income for Q3 2025 was $855,000, a significant improvement from a net loss of $3.2 million in Q3 2024 [7][8] - Adjusted EBITDA for consolidated operations increased by 36% to $3.3 million from $2.4 million in Q3 2024 [9][13] Operational Highlights - The company sold eight franchise licenses in Q3 2025, compared to seven in Q3 2024 [7] - The total clinic count as of September 30, 2025, was 962, with 884 franchised and 78 company-owned or managed [7] - System-wide sales reported were $127.3 million, a decline of 1.5% [7] Strategic Initiatives - The company is focusing on refranchising its corporate portfolio and enhancing patient acquisition strategies [4] - Investments in digital marketing and search engine optimization are being made to improve brand visibility and patient experience [4] - A three-tiered pricing pilot for the wellness plan was initiated in November 2025 [4] Balance Sheet and Cash Flow - Unrestricted cash at September 30, 2025, was $29.7 million, an increase from $25.1 million at the end of 2024 [10] - The company has a currently undrawn line of credit with JP Morgan Chase, providing access to $20 million through August 2027 [10] Guidance and Future Outlook - The company updated its guidance for system-wide sales to range from $530 million to $534 million for the full year of 2025 [18] - Comp sales guidance was adjusted to a range of (1)% to 0% for the year, down from previous expectations of low-single-digit growth [18]